In patients with at least one valid record, >90% of records were valid for 40.7% of patients (n=6065) and <30% of records were valid for 7.4% of patients (n=1106). A total of 11 861 patients were male and 3 013 were female (79.7% and 20.3%, respectively). These proportions correlate well with the sex distribution of patients with newly confirmed diagnoses of HIV infection in Germany reported to the RKI through the national surveillance between 1993 and 2009 (Table 2) [11]. The mean age of the patients at first visit increased continuously from 36.2 years in 1999 to 38.6 years in 2009 [analysis of variance (anova); P<0.001].
Consistently, the national HIV surveillance data show an increase of mean age at time of diagnosis from 34.6 years (s=11.01) in 1999 to 37.3 years (s=11.19) in 2009. Female patients were younger than male patients
at the first contact (anova; P<0.001). Olaparib in vitro A characterization of the ClinSurv HIV cohort by transmission group category is presented in Table 2. In Table 2, the cohort data are compared with data from the German national HIV surveillance [11] to assess the representativeness of the cohort data. The comparison reveals that MSM and injecting drug users (IDUs) were overrepresented in the cohort, while persons with a heterosexual transmission risk (HET) and, especially, those originating from high-prevalence countries (HPCs) were underrepresented. Patients from Lumacaftor cell line Germany were more likely to be enrolled in the cohort (76.3% compared with 68.7% in the national HIV surveillance). Patients originating from sub-Saharan Africa were less likely to be enrolled (10.3% and 13.2%, respectively) (data Adenosine triphosphate not shown). However, enrolment of patients from Eastern Europe and sub-Saharan Africa tended to increase over time (P<0.001 and P<0.05, respectively, by χ2 test for trend), whereas enrolment of patients from Germany decreased (P<0.001 by χ2 test for trend). At the end of 2009, approximately 50 000 PLWHA were thought to be under medical care and treatment in hospitals or with
private practitioners. In the second half of 2007 and the first half of 2009, in total 9757 patients had valid observational reports in the ClinSurv HIV database. The data suggest that the ClinSurv HIV cohort included the records of nearly one-fifth of all HIV-infected patients in clinical care in Germany in the middle of 2009. The distribution of disease stage at first registration changed over time. During the implementation period (1999–2000), 62.0% of new patients were stage CDC-A, a proportion that increased to 64.9% in 2003–2004. In the same period, the proportion of stage CDC-C at the time of first registration decreased from 25.0% to 24.2%. Cumulatively, the 3956 patients in the cohort with documented stage CDC-C and who were not known to be deceased in mid 2009 represented approximately 35% of the estimated 11 300 people living with AIDS in Germany at that time [5].
Related posts:
- KRN 633 KRN633 Range of Valid and poorly understood
- One crucial challenge relates to whether this can be a valid phen
- Survival of pomalidomide-treated PMF patients was compared to other PMF patients
- Eleven patients (55%) died, 9 patients (45%) are alive The 5 yea
- Sorafenib has subsequently been shown to significantly expand PFS in patients wi